Interview with Sabine Dandiguian, President, Janssen-Cilag France
Janssen-Cilag is involved in not only selling its products in France but research and production as well. As France is a leading subsidiary, can you speak to the importance of…
Address: 1, Rue Camille Desmoulins, Issy les Moulineaux 92787,France
Tel: +33 (0)1 55 00 45 00
Web: http://www.janssen-france.fr/
Janssen-Cilag companies operate in virtually all countries of the world and employees 6,000 people throughout Europe, 1600 of which are in France, to develop and market innovative, high-quality medicines.
In 2008 the company achieved a turnover of 788 million euros while investing 8.5 million euros in research and development in oncology and virology.
* Pain management
* Psychiatry
* Neurology
* Gastrointestinal disease
* Fungal disease
Janssen-Cilag is involved in not only selling its products in France but research and production as well. As France is a leading subsidiary, can you speak to the importance of…
A roundup of the top stories coming out of France’s pharma industry, including Sanofi’s consumer health unit spinout and EUR 40 million investment in antibody bioproduction; the French govenment’s unprecedented…
At the 13th annual meeting of French life sciences think tank, G5 Santé – which represents the leaders of eight major French health and life sciences companies, including bioMérieux, Sanofi,…
In conversation at ESMO 2024, Pierre Fabre’s R&D Head Francesco Hofmann outlines some of the key data readouts for the company’s oncology portfolio from this year’s conference, how it is…
Lionel Collet, president of France’s Haute Autorité de Santé (HAS), explains the role of the independent public authority, which extends beyond health technology assessment (HTA) to clinical practice guidelines and…
FACOPHAR Santé is the French association for actors operating in the natural and herbal remedies field. In conversation with PharmaBoardroom, long-term president Jacques Vernin explains how the organisation promotes French…
The biggest stories from French healthcare and pharma, including AstraZeneca’s acquisition of Amolyt Pharma; protests over Sanofi layoffs; Pierre Fabre’s purchase of Kinnate Biopharma’s experimental pan-RAF inhibitor, and French biotech…
As president of the French League Against Cancer, Dr Daniel Nizri highlights the organization’s 106-year legacy of fighting cancer through research funding, health promotion, patient support, and advocacy. He discusses…
After offloading its consumer healthcare division in 2022 and in view of the gradual erosion of its top seller, Somatuline, Ipsen opted to aggressively seek external assets to enrich its…
France is the third most significant clinical research destination in Europe, participating in 50 percent of the trials initiated across the continent. While favourable government policies and unique strengths such…
Hubert Mechin, president of AFCROs, the association that groups clinical research organisations in France, details the organisation’s efforts to help its members stay abreast of changes in the European regulatory…
With revenues projected to reach USD 27.01 billion in 2024, France’s pharma market is ranked fifth globally. Home to a number of well-established local pharma players and a sought-after destination…
Just five months after taking office, Aurélien Rousseau resigned from his role as health minister in protest against France’s recently adopted immigration law. Interim replacement Agnès Firmin Le Bodo, the…
See our Cookie Privacy Policy Here
